Prescient Therapeutics Ltd has released a press release.
Response to Aware Query
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- PTX-200 Phase 1b Breast Cancer Trial Results
- March 2018 Investor Presentation
- December 2017 Appendix 4C - Quarterly
- Clinical Trial Updates
- Clinical Hold Lifted on PTX-200 Breast Cancer Trial
Later from Prescient Therapeutics
- March 2018 Appendix 4C - Quarterly
- US Patent Granted for PTX-200 for Ovarian Cancer Treatment
- June 2018 Appendix 4C - Quarterly
- PTX-200 AML Study Expanded
- Appendix 4E and 2018 Annual Report
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics